Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

377
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
377
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

380
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
380
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

703
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
703
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

454
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
454
Drug Therapy01:28

Drug Therapy

97
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
97

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Apathy in Parkinson's Disease: Distinguishing Overlapping Symptoms Via Network Analysis.

Movement disorders clinical practice·2026
Same author

True vignettes: interesting, illustrative examples of behavioral abnormalities in people with Parkinson's disease.

Arquivos de neuro-psiquiatria·2026
Same author

Cognitive Fluctuations, Neuropsychiatric Burden, and Quality of Life in Moderate-Advanced Dementia With Lewy Bodies: The Role of Dysautonomia.

Neurology·2026
Same author

Perspective: Depression in Persons with Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

A Holistic Wellness Prescription for Parkinson's Disease: Evidence-Based Perspectives and Unmet Needs.

Movement disorders clinical practice·2025

Video Experimental Relacionado

Updated: Sep 10, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.5K

¿Necesitamos medicamentos para los síntomas psiquiátricos específicamente para la enfermedad de Parkinson?

Kelly A Mills1, Gregory M Pontone2,3

  • 1Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Journal of Parkinson's disease
|August 21, 2025
PubMed
Resumen

El desarrollo de nuevos medicamentos para los síntomas psiquiátricos en personas con enfermedad de Parkinson (EP) requiere una mayor atención a los objetivos del tratamiento. Esta revisión examina los tratamientos farmacológicos actuales y propone direcciones futuras para mejorar las terapias.

Palabras clave:
La enfermedad de ParkinsonAnsiedadla apatíala depresióncontrol de los impulsosLa psicosis

Más Videos Relacionados

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

Videos de Experimentos Relacionados

Last Updated: Sep 10, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
16:57

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

26.5K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.9K
Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.1K

Área de la Ciencia:

  • La neurociencia
  • La psiquiatría
  • Farmacología

Sus antecedentes:

  • Los síntomas psiquiátricos son muy frecuentes en las personas con enfermedad de Parkinson (PWP), que a menudo aparecen en la fase prodroma.
  • Estos síntomas están intrincadamente relacionados con las deficiencias motoras y sus tratamientos, lo que sugiere posibles conexiones mecánicas.

Objetivo del estudio:

  • Revisar los tratamientos farmacológicos existentes para los síntomas psiquiátricos en pacientes con PWP.
  • Explorar futuras estrategias y objetivos para el desarrollo de nuevos medicamentos para los síntomas psiquiátricos en la EP.

Principales métodos:

  • Revisión de la literatura de las pruebas actuales para los tratamientos farmacológicos.
  • Exploración de posibles vínculos mecánicos entre los síntomas psiquiátricos y motores.

Principales resultados:

  • Se discuten los tratamientos farmacológicos actuales para los síntomas psiquiátricos en PWP.
  • Se destaca la compleja interacción entre los síntomas psiquiátricos, los síntomas motores y los tratamientos.

Conclusiones:

  • Se necesitan más investigaciones sobre las conexiones mecanicistas.
  • Los nuevos objetivos y enfoques terapéuticos son esenciales para desarrollar medicamentos efectivos para los síntomas psiquiátricos de la enfermedad de Parkinson.